Brief: China Medical System Says New Drug Application Of Tildrakizumab Injection Approved In China
May 30 (Reuters) - China Medical System Holdings Ltd
0867.HK :
* NEW DRUG APPLICATION OF TILDRAKIZUMAB INJECTION APPROVED
IN
CHINA
* NDA OF TILDRAKIZUMAB INJECTION APPROVED BY NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION
Further company coverage: 0867.HK
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says